Regulatory Approvals for Aspen’s Generic Injectable Semaglutide in Brazil and South Africa

ASPEN PHARMACARE HOLDINGS LIMITED ("Aspen" or the "Company")
(Incorporated in the Republic of South Africa)
Registration number: 1985/002935/06
JSE Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94


REGULATORY APPROVALS FOR ASPEN’S GENERIC INJECTABLE SEMAGLUTIDE IN BRAZIL AND SOUTH AFRICA

Aspen is pleased to announce that it has received regulatory approval for its generic
injectable semaglutide in both Brazil and South Africa. As previously announced in July 2026,
regulatory approval for the product has also been received in Canada.

Semaglutide is indicated, in combination with diet and exercise, for the treatment of adults
with type 2 diabetes mellitus to improve glycaemic control.

Commercialisation is expected to commence in Canada, Brazil and South Africa over the next
few months.


Durban

11 November 2026

Sponsor

Investec Bank Limited
Date: 11/11/2026 09:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.